Mindray snaps up Chinese analytic systems maker; FDA collaboration to monitor eye condition associated with cataract surgery;

> Mindray Medical International ($MR) has agreed to buy a controlling stake in Hunan Changsha Tiandiren Biotech. It has not disclosed any terms of the deal. Report

> The FDA and other organizations unveiled a program to monitor medical devices used in cataract surgery in an effort to stem outbreaks of a rare, inflammatory condition associated with the procedure. FDA release

> Nanosphere ($NSPH) has obtained CE IVD Mark for its gram-positive blood culture nucleic acid test on the automated sample-to-result Verigene system. Nanosphere release

> Women with Poly Implant Prothese breast implants made by a now-defunct French company have no reason to have them removed but should seek medical advice if they believe they have ruptured, British health officials said. Item

> Mindray Medical International ($MR) has entered an agreement with Novation allowing the latter's more than 65,000 members and affiliates to purchase the M7 and M5 ultrasound systems. Mindray release

> The state of Maryland is being urged to require "rigorous internal and external review of stenting practices in hospitals in the state after an advisory group recommended a lower standard." The call comes after The Baltimore Sun reported John Chung-Yee Wang of the Union Memorial Hospital in Baltimore is accused of improper stenting in three separate legal claims. News

> The Austen BioInnovation Institute in Akron and the FDA are collaborating to support and develop regulatory science for the safe and effective use of biomaterials in medical devices. Release

And Finally... Former NFL star Willie Gault has been accused by U.S. regulators of taking part in a scheme to artificially inflate the stock of a medical device company he managed. Report

Suggested Articles

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.